Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Pevonedistat (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- 24 Apr 2018 Planned End Date changed from 30 Apr 2021 to 31 Mar 2021.
- 24 Apr 2018 Planned primary completion date changed from 30 Jun 2020 to 31 May 2020.
- 24 Apr 2018 Status changed from not yet recruiting to recruiting.